Skip to main content

Rheumatoid Arthritis: Tuberculosis Screening (Recommended for eMeasure Trial Approval)

CBE ID
2522
Endorsement Status
Approved for Trial Use
1.1 New or Maintenance
Maintenance
Previous Endorsement Cycle
Spring 2019
Is Under Review
No
Next Maintenance Cycle
Fall 2025
1.3 Measure Description

Percentage of patients 18 years and older with a diagnosis of rheumatoid arthritis who have documentation of a tuberculosis (TB) screening performed within 6 months prior to receiving a first course of therapy using a biologic disease-modifying anti-rheumatic drug (DMARD).

    • 1.14 Numerator

      Any record of TB testing documented or performed (PPD, IFN-gamma release assays, or other appropriate method) in the medical record in the 12 months preceding the biologic DMARD prescription.

    • 1.15 Denominator

      Patients 18 years and older with a diagnosis of rheumatoid arthritis who are seen for at least one face-to-face encounter for RA who are newly started on biologic therapy during the measurement period.

    • Exclusions

      N/A

    • 1.13a Data dictionary not attached
      No
    • Most Recent Endorsement Activity
      Approved for Trial Use Primary Care and Chronic Illness Spring Cycle 2019
      Initial Endorsement
      Last Updated
    • Steward
      American College of Rheumatology
      Steward Organization POC Email
      [email protected]
      Steward Organization Copyright

      Copyright (c) 2013, American College of Rheumatology

    • Risk Adjustment
      No risk adjustment or risk stratification
      Risk adjustment approach
      Off
      Risk adjustment approach
      Off
      Conceptual model for risk adjustment
      Off
      Conceptual model for risk adjustment
      Off